Uncertainty Over BRCA Testing Reimbursement Remains
This article was originally published in The Gray Sheet
Executive Summary
In recently updated clinical lab fee schedule rates, Medicare payment for BRCA1 and BRCA2 genetic testing goes down from $2,795 to $1,438, but Myriad Genetics believes the change might be a clerical error, repeating an issue from September.
You may also be interested in...
MolDx Labs Question Missing Medicare Payment Amounts For Some Test Codes
Clinical laboratories plan to talk to CMS about its decision to list only 65 out of 114 new molecular pathology codes when it released revised gap-fill pricing Sept. 30, as well as concerns about perceived changes to the gap-fill regulation.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.